Long term improvement
Neovascularisation is a cascade effect where VEGF play a major role and is the target for pharmacological intervention.
Anti-VEGF therapies effectively block neovascularisation on nuumerous studies, but none of these drugs have any effect on mature retinal vessels. Most of these anti-angiogenic drugs currently tested are effective in preventing the development rather than regression of already established vessels. That is why combination therapies are being tested (with Visudyne). With exceptions, I hope, Squalamine and Combretastatin, that effectively show regression in preclinical studies for they have a different mechanism of action.
Beside that, I don't know when Oxigene started effectively their ongoing trial, but based on a similar schedule than the one from Genaera, I expect some news (interim data maybe?) within 2-3 months.
What do you think?
Market Data 
Markets 
AI
